Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10113993 | 0.83 | LMNA (0.68) | GAALMNAALDH1A1ALOX15HSD17B10 | |
| SCHEMBL10113988 | 0.74 | RXFP1 (0.62) | MAOBGAALMNAALDH1A1ALOX15 | |
| SCHEMBL20161760 | 0.73 | TRPA1 (0.48) | ALDH1A1ALOX15CYP1A2SMN1; SMN2MAPK1 | |
| SCHEMBL684090 | 0.72 | ADORA2B (0.54) | LMNAALDH1A1CYP1A2SMN1; SMN2MAPK1 | |
| SCHEMBL11702678 | 0.72 | ADORA2B (0.64) | LMNASMN1; SMN2MAPK1ADORA2BRXFP1 | |
| SCHEMBL11635125 | 0.71 | ADORA2B (0.58) | LMNASMN1; SMN2MAPK1ADORA2BRXFP1 | |
| SCHEMBL7020240 | 0.71 | ADORA2B (0.62) | LMNAALDH1A1SMN1; SMN2MAPK1ADORA2B | |
| SCHEMBL5471122 | 0.71 | ADORA2B (0.62) | LMNASMN1; SMN2MAPK1ADORA2BRXFP1 | |
| SCHEMBL11632640 | 0.70 | ADORA2B (0.57) | LMNASMN1; SMN2MAPK1ADORA2BRXFP1 | |
| SCHEMBL11702624 | 0.70 | ADORA2B (0.57) | LMNAALDH1A1SMN1; SMN2MAPK1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | MAOB 669/4885CASP3 1188/4885GAA 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.